Portuguese biotechnology organisation Lxbio has received the Outstanding Innovation Award at the World Conference on Targeting Phage Therapy in Valencia, Spain, for their work on engineered bacteriophage platforms for targeted cancer therapy and next-generation precision biologics.
The award recognises a program that seeks to expand the role of bacteriophages beyond their traditional application in infectious diseases and into the emerging field of programmable biological therapeutics. According to the conference organisers, the distinction reflects:
-
The scientific originality of the approach;
-
Its industrial vision;
-
Its potential to contribute to the future evolution of phage-based technologies.
A Shift in Phage Technology Paradigms Historically, bacteriophages have primarily been studied as natural predators of bacteria. The platform being developed by Lxbio explores a fundamentally different opportunity: the use of engineered bacteriophages as adaptable biological systems capable of supporting highly targeted therapeutic strategies in oncology and other areas of precision medicine.
Currently in preclinical development, the program is designed as a modular technology platform rather than a single-product initiative. While its initial focus is oncology, the underlying architecture has been conceived to support broader applications across multiple therapeutic settings. The long-term objective is to establish a new class of precision biologics capable of integrating targeting, therapeutic delivery, and additional biological functionality within a single programmable construct.
Global Industry Recognition The award was presented at one of the leading international conferences dedicated to bacteriophage science, clinical translation, and industrial development, bringing together researchers, clinicians, biotechnology companies, and regulatory experts from across Europe, North America, and Asia.
Beyond the scientific recognition, the distinction highlights the growing ability of Portuguese biotechnology organisations to generate advanced therapeutic technologies, intellectual property, and platform innovations with international relevance. It also reflects increasing interest in biologically programmable systems as a potential foundation for the next generation of precision medicine.
The program forms part of a broader effort by Lxbio and SEAPOWER to explore new therapeutic paradigms at the intersection of biotechnology, synthetic biology, and precision medicine, with the goal of translating emerging scientific concepts into scalable and clinically meaningful innovations.
